Terms: = Pancreatic cancer AND PIK3CA, MGC142161, 5290, ENSG00000121879, P42336, MGC142163, p110-alpha, PI3K AND Clinical Outcome
10 results:
1. Epigenetic upregulation of MNAT1 by SMYD2 is linked to pi3k/AKT activation and tumorigenesis of pancreatic adenocarcinoma.
Xu Z; Liu Y; Pan Z; Qin L
Histol Histopathol; 2024 Feb; 39(2):263-277. PubMed ID: 37232506
[TBL] [Abstract] [Full Text] [Related]
2. Activation of the pi3k-AKT signaling pathway by SPARC contributes to the malignant phenotype of cholangiocarcinoma cells.
Deng S; Zhang L; Li J; Jin Y; Wang J
Tissue Cell; 2022 Jun; 76():101756. PubMed ID: 35217388
[TBL] [Abstract] [Full Text] [Related]
3. Comprehensive Analysis of Expression, Prognostic Value, and Immune Infiltration for Ubiquitination-Related FBXOs in pancreatic Ductal Adenocarcinoma.
Zhang Y; Liu Q; Cui M; Wang M; Hua S; Gao J; Liao Q
Front Immunol; 2021; 12():774435. PubMed ID: 35046938
[TBL] [Abstract] [Full Text] [Related]
4. Genome-Derived Classification Signature for Ampullary Adenocarcinoma to Improve clinical cancer Care.
Chakraborty S; Ecker BL; Seier K; Aveson VG; Balachandran VP; Drebin JA; D'Angelica MI; Kingham TP; Sigel CS; Soares KC; Vakiani E; Wei AC; Chandwani R; Gonen M; Shen R; Jarnagin WR
Clin Cancer Res; 2021 Nov; 27(21):5891-5899. PubMed ID: 34433650
[TBL] [Abstract] [Full Text] [Related]
5. Deoxycholic acid modulates the progression of gallbladder cancer through N
Lin R; Zhan M; Yang L; Wang H; Shen H; Huang S; Huang X; Xu S; Zhang Z; Li W; Liu Q; Shi Y; Chen W; Yu J; Wang J
Oncogene; 2020 Jun; 39(26):4983-5000. PubMed ID: 32514152
[TBL] [Abstract] [Full Text] [Related]
6. Identification of a 4-miRNA signature as a potential prognostic biomarker for pancreatic adenocarcinoma.
Wang ZX; Deng TX; Ma Z
J Cell Biochem; 2019 Oct; 120(10):16416-16426. PubMed ID: 31297864
[TBL] [Abstract] [Full Text] [Related]
7. Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma.
Abdel-Wahab R; Varadhachary GR; Bhosale PR; Wang X; Fogelman DR; Shroff RT; Overman MJ; Wolff RA; Javle M
J Hematol Oncol; 2018 May; 11(1):71. PubMed ID: 29843755
[TBL] [Abstract] [Full Text] [Related]
8. KRAS, BRAF, and pik3ca mutations, and patient prognosis in 126 pancreatic cancers: pyrosequencing technology and literature review.
Zhou L; Baba Y; Kitano Y; Miyake K; Zhang X; Yamamura K; Kosumi K; Kaida T; Arima K; Taki K; Higashi T; Imai K; Hashimoto D; Yamashita Y; Chikamoto A; Beppu T; Tan X; Baba H
Med Oncol; 2016 Apr; 33(4):32. PubMed ID: 26927447
[TBL] [Abstract] [Full Text] [Related]
9. The flavonoid p-hydroxycinnamic acid exhibits anticancer effects in human pancreatic cancer MIA PaCa-2 cells in vitro: Comparison with gemcitabine.
Yamaguchi M; Murata T; El-Rayes BF; Shoji M
Oncol Rep; 2015 Dec; 34(6):3304-10. PubMed ID: 26397991
[TBL] [Abstract] [Full Text] [Related]
10. Insulin-like growth factor signaling as a therapeutic target in pancreatic cancer.
Rieder S; Michalski CW; Friess H; Kleeff J
Anticancer Agents Med Chem; 2011 Jun; 11(5):427-33. PubMed ID: 21492074
[TBL] [Abstract] [Full Text] [Related]
